Superficial Surgical Site Infections in Primary Total Joint Arthroplasty: A Retrospective Analysis of Topical Anti-Biofilm Therapy.
| Autor: | Kelly JP; Orthopaedic Surgery, The Hughston Foundation, Columbus, USA.; Orthopaedic Surgery, The Hughston Clinic, Columbus, USA.; Orthopaedic Surgery, Jack Hughston Memorial Hospital, Phenix City, USA., Bae AS; Orthopaedic Surgery, Jack Hughston Memorial Hospital, Phenix City, USA., Taunton J; Orthopaedic Surgery, The Hughston Clinic, Columbus, USA., Jardaly A; Orthopaedic Surgery, The Hughston Clinic, Columbus, USA., Harris RM; Trauma and Orthopaedics, The Hughston Clinic, Columbus, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Cureus [Cureus] 2023 May 25; Vol. 15 (5), pp. e39490. Date of Electronic Publication: 2023 May 25 (Print Publication: 2023). |
| DOI: | 10.7759/cureus.39490 |
| Abstrakt: | Introduction Surgical site infections (SSI) following orthopedic procedures can cause significant morbidity and mortality, particularly in total joint arthroplasty. Biofilm formation in surgical wounds has made it difficult to prevent and treat these infections. SURGX® Antimicrobial Wound Gel (Next Science, Jacksonville, Florida, USA) was developed to disrupt biofilm formation but has not been evaluated in prophylactic use in total joint arthroplasty to prevent superficial SSI. Methods A retrospective chart review was performed at a single institution comparing the rate of SSI in patients undergoing primary total hip arthroplasty (THA) and total knee arthroplasty (TKA). SSI data were collected from patients with standard postoperative dressings (Group A: Control) and patients with SURGX® applied as part of a standardized dressing following THA/TKA (Group B: Study). Rates of SSI were compared. Results SURGX® was administered to 120 patients, including 91 TKAs and 29 THAs. The overall infection rate in this cohort was 2.5%. No superficial site infections developed. The control group constituted 566 patients, with 386 TKAs and 180 THAs. The infection rate was 1.24%, which included one superficial infection. Binary logistic regression did not show different odds of developing infections with the use of SURGX® (OR = 2.23, 95% CI: 0.54-9.13, p = 0.27). Conclusion In our small retrospective study, Next Science SURGX® Antimicrobial Wound Gel did not demonstrate a statistically significant difference in the rate of superficial SSI in total joint arthroplasty; however, Group B did not have any superficial SSI. Competing Interests: The authors have declared financial relationships, which are detailed in the next section. (Copyright © 2023, Kelly et al.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|